​Vertex raises price of top-selling cystic fibrosis drug for first time - (Boston Business Journal via NewsPoints Desk)

  • Vertex Pharmaceuticals has increased the price of its cystic fibrosis therapy Orkambi for the first time, Boston Business Journal reported Wednesday.

  • According to Cowen & Co. analyst Phil Nadeau as well as a company spokesperson, the price of the drug was increased by 5 percent to about $273 000 per year before discounts.

  • The therapy, which was cleared by regulators in July 2015, generated $980 million in sales last year.

  • Vertex has also only raised the price of its second cystic fibrosis drug, Kalydeco, by 4.5 percent in January 2013.

  • The drugmaker received criticism earlier this year for lobbying federal regulators to omit ballot questions on price transparency from their annual meetings.

  • Last month, shareholders rejected a proposal that would have required the company to disclose information regarding its lobbying efforts.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.